Delivery Order SPE2DB22D2206-SPE2DB26FDR56
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,120.74 to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 500 mg vials. The contract, awarded on August 8, 2025, with an ultimate completion date of August 11, 2025, operates under firm fixed pricing with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $44,261.94 to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 2 GM vials. This contract, issued on August 6, 2025, with an ultimate completion date of August 7, 2025, operates under a firm fixed-price arrangement with no set-aside designation, indicating competitive award. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $2,580.30 to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 1 GM vials, with an ultimate completion date of September 5, 2025. This is a firm fixed-price, non-set-aside contract with performance at the contractor's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is...
- The Defense Logistics Agency awarded a $1,867.90 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Cyclophosphamide 500 mg vials, with an ultimate completion date of September 17, 2025. This firm fixed-price contract represents a non-set-aside award issued through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement needs and...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $26,197.80 on July 22, 2025, for the supply of Cyclophosphamide 2 GM vials, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order contract to AmerisourceBergen Drug Corp for Cyclophosphamide 1 GM/5 ML vials (5 ML quantity) valued at $7,649.10. This is a firm fixed price delivery order with an ultimate completion date of September 24, 2025, awarded on September 23, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. Performance will be completed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 500 mg vials, valued at $1,120.74. The award, issued on August 19, 2025, represents a firm fixed-price delivery order under a competitive, non-set-aside procurement. The pharmaceutical product will be delivered to the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 20, 2025. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Cyclophosphamide 50 mg capsules (100 count) valued at $1,942.93. This is a firm fixed-price delivery order with a completion deadline of September 9, 2025, and no set-aside designation was utilized. The work will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen Drug...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation's Corporate Office Division. The $3,735.80 contract is for the delivery of Cyclophosphamide 500 mg vials, a critical pharmaceutical product. The award has an ultimate completion date of August 19, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025, which enables the government to...
- This is a delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the supply of 4,565,732,286 units of Cyclophosphamide 2 GM vials, a chemotherapy drug. The $70,284.14 firm-fixed-price contract has an ultimate completion date of September 10, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB26FDR56Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,293.66 to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 2 GM vials. This competitively awarded, firm fixed-price contract with no set-aside designation was executed on October 17, 2025, with an ultimate completion date of October 20, 2025. The pharmaceutical product will be supplied from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. As a comprehensive global pharmaceutical support vehicle, the IDC enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs and other federal agencies, including the Defense Health Agency and U.S. Coast Guard. Cyclophosphamide is a critical chemotherapy agent used in military and veteran healthcare systems, and this delivery order represents one of numerous small-value transactions executed under the larger pharmaceutical prime vendor contract.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.3k | 10/17/25 |